

Clinical characteristics of patients infected with the novel 2019 coronavirus (SARS-Cov-2) in
Guangzhou, China

Yaping Wang¹, Baolin Liao¹, Yan Guo², Feng Li¹, Chunliang Lei¹, Fuchun Zhang¹, Weiping Cai¹, Wenxin Hong¹, Yu Zeng², Shuang Qiu, Jian Wang¹, Yueping Li¹, Xilong Deng¹, Jianping Li¹, Guangming Xiao¹, Fengxia Guo¹, Xunxi Lai¹, Zhiwei Liang¹, Xueliang Wen¹, Pinghong Li¹, Qian Jiao¹, Fangfei Xiang¹, Yong Wang¹, Chenghui Ma¹, Zhiwei Xie¹, Weiyin Lin¹, Yanrong Wu¹, Xiaoping Tang¹, Linghua Li¹, Yajuan Guan¹

¹ Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China

² Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China

† Wang YP¹, Liao BL¹, Guo Y² **These authors contributed equally to this work.**

***Corresponding authors:**

Yujuan Guan, M D,

Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng East Road, Yuexiu District, Guangzhou, Guangdong, 510060, China.

Tel: +86 20 83710397

E-mail : gz8hgyj@126.com

OR

Linghua Li, PhD,

Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng East Road, Yuexiu District, Guangzhou, Guangdong, 510060, China.

Tel: +86 20 83710397

E-mail: llhehiza@126.com

OR

Xiaoping Tang PhD

Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng East Road, Yuexiu District, Guangzhou, Guangdong, 510060, China.

Tel: +86 20 83710397

E-mail: tangxiaopinggz@163.com

Accepted Manuscript

Background: The clinical manifestations and factors associated with the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections outside of Wuhan are not clearly understood.

Methods: All laboratory-confirmed cases with SARS-Cov-2 infection hospitalized and monitored in Guangzhou Eighth People's Hospital were recruited from 10 Jan to 20 Feb.

Results: A total of 275 patients were included in this study. The median patient age was 49 years, and 63.6% of them had exposure to Wuhan. The median virus incubation period was 6 days. Fever (70.5%) and dry cough (56.0%) were the most common symptoms. A decreased albumin level was found in 51.3% of patients, lymphopenia in 33.5%, and pneumonia based on chest computed tomography CT in 86%. Approximately 16% of patients (n = 45) had severe disease, and there were no deaths. Compared with patients with non-severe disease, those with severe disease were older, had a higher frequency of coexisting conditions and pneumonia, and had a shorter incubation period (all, $P < 0.05$). There were no differences between patients who likely contracted the virus in Wuhan, and those that had no exposure to Wuhan. Multivariate logistic regression analysis indicated that older age, male sex, and decreased albumin level were independently associated with disease severity.

Conclusions: The frequency of patients with a severe SARS-CoV-2 infection in Guangzhou, China, was lower than in Wuhan, China. Early diagnosis and treatment is important for controlling SARS-CoV-2 infections.

Keywords: SARS-CoV-2; epidemiology; clinical characteristics; risk factors; viral load

Introduction

In December 2019, cases of unexplained pneumonia related to the Huanan seafood market began appearing in Wuhan, Hubei Province, China(1). It was subsequently determined the pathogen was a novel coronavirus, and the gene sequence was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses (2). The virus is the seventh member of the known coronavirus family that is able to infect humans(3). Since the virus is similar to SARS coronavirus (SARS-CoV), which is a member of the subgenus *Sarbecovirus* (Beta-CoV lineage B)(4), it was subsequently renamed SARS-CoV-2. The pneumonia caused by the virus was named Corona Virus Disease 2019 (COVID-19).

The outbreak of SARS-CoV-2 infection has become a global health concern. As of May 6, 2020, there were 82,885 document cases in China, and 4,633 deaths due to the disease (<http://my-h5news.app.xinhuanet.com/h5activity/yiqingchaxun/index.html>).

Although the number of infected persons has increased rapidly, clinical investigations of patients, especially those outside of Wuhan, are lacking. Chen et al. (5) studied the clinical features of 99 patients with COVID-19, and found that SARS-Cov-2 was more likely to infect older men with comorbidities, and lead to acute respiratory distress syndrome (ARDS). Several recent studies(6, 7) have indicated that the rapid spread of the virus is due to human-to-human transmission, and have found evidence of familial cluster cases. While Wang et al.(8) studied 138 hospitalized patients with COVID-19 in Wuhan: 41% of the patients were suspected to have been infected by in-hospital transmission of SARS-CoV-2, 26% of the patients required treatment in the intensive care unit (ICU), and the mortality rate was 4.3%.

As of May 6, 2020, Guangdong Province, China, has the most confirmed cases outside of Hubei (http://wsjkw.gd.gov.cn/xxgzbdfk/content/post_2988153.html). Guangzhou is the economic and healthcare center of Guangdong Province, and is one of most popular cities for migrant workers. The Guangzhou Eighth People's Hospital is major center for the care of patients with new emerging infectious disease in Guangdong. Thus, the purpose of this study was to examine the epidemiological, clinical, and laboratory characteristics of patients with SARS-Cov-2 infections in Guangzhou.

Methods

Study design and participants

The records of patients with COVID-19 diagnosed by the Guangdong Center for Disease Control (CDC) who were admitted to the Guangzhou Eighth People's Hospital from January 20, 2020 to February 10, 2020 were retrospectively reviewed. The study was approved by Guangzhou Eighth People's Hospital Ethics Committee and written informed consent was obtained from patients involved before enrolment when data were collected retrospectively.

For the analyses, patients were divided into those with severe disease and those with non-severe disease based on World Health Organization (WHO) interim guidance(9). Patients were also divided into an “imported” group and local group. Imported group patients were those who had been to Wuhan within 14 days or resident of Wuhan before admission, and the local group were patients who had not left Guangdong during the past 1 month. The incubation period was defined as the duration of time from the contact with the source of transmission to the onset of symptoms. Fitness for discharge was based on abatement of fever

for at least three days, with improvement of chest CT findings, and viral clearance in upper respiratory tract nasopharyngeal samples.

Data collection

Data were obtained from the patient medical records database, and included demographic and epidemiological characteristics, clinical symptoms and signs, and laboratory test and radiographic imaging results. Laboratory test results collected included complete blood cell count (CBC), tests of coagulation function and liver and kidney function, electrolyte levels, C-reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase (LDH), and creatine kinase (CK). The primary radiographic assessment was chest CT. If there were missing data, or clarifications were needed, the information was obtained by communicating directly with the patient, the attending doctor, or other data providers. All data used in the analyses were checked by two doctors.

The end points included the rate of severe infections, complications, the need for ICU admission, the need for mechanical ventilation, and death. These endpoints were not applied to a fixed time range (i.e. within 28 days) as clinical observations were still in progress.

Real-time reverse transcription polymerase chain reaction (RT-PCR)

All patients that were transferred to the Guangzhou Eighth People's Hospital were diagnosed by a throat swab nucleic acid test administered by the Guangdong CDC. On admission, respiratory samples were taken to determine viral load by a RT-PCR assay. In brief, upper respiratory throat swab samples were collected from all patients after admission, and the samples were stored in virus medium. An RNA Isolation Kit (Da An Gene Co., Ltd.,

Guangzhou, China) was used to extract viral RNA from the samples. RT-PCR was performed using a RNA Detection Kit for SARS-CoV-2 (Da An Gene Co., Ltd.). The ORF1ab and N genes of SARS-CoV-2 were the amplification target regions. The receiver operating characteristic (ROC) curve method was used to determine the internal standard reference cycle threshold (Ct) value, which was determined to be 40. If the Ct value was ≤ 40 , the sample was considered to be positive; if the value was > 40 the sample was considered to be negative.

Statistical analysis

Since all the continuous variables in this study were not normally distributed, continuous variables were presented as median and interquartile range (IQR). Categorical variables were described as numbers and percentages. The Wilcoxon-Mann-Whitney U-test was used to test differences between groups for continuous variables as they did not follow a normal distribution. The chi-square test was used to examine differences of categorical variables. Variables with a value of $P < 0.10$ in bivariate analysis were included in the multivariate logistic regression analysis. A forward stepwise binary logistic regression was used for multivariate analysis. Variables with $P < 0.05$ were retained in the final regression model. SPSS version 20.0 (IBM Corp., USA) was used for data analysis.

Results

Demographic and clinical characteristics of patients

A total of 275 patients with laboratory confirmed SARS-Cov-2 infections were included in the analysis. The median age of the patients was 49 years (IQR: 34-62 years), 41.3% were at least 50 years old, 47.7% were males, and 33.1% had at least 1 coexisting medical condition. None of the patients described exposure to the Huanan seafood market, and none of the patients were healthcare workers. Based on the WHO definition(9), 230 (83.6%) patients had non-severe disease and 45 (16.4%) patients had severe disease. Compared with the non-severe group, patients with severe disease were older and had a much higher frequency of coexisting medical conditions. Additionally, the frequency of imported cases was higher in the severe group than in the non-severe group (80.0% vs. 60.4%, $P = 0.013$) (Table 1). The median incubation time for all patients was 6 days; however, the incubation time was significantly shorter in the severe group than in the non-severe group (4 days vs. 6 days, $P = 0.004$). The median interval between hospital admission and symptom onset was 5 days; but it was significantly longer in the severe group than in the non-severe group (5 days vs. 4 days, $P = 0.034$).

In all patients, the most common symptoms at the onset of illness were fever (70.5%), dry cough (56%), sputum production (22.6%), and sore throat (13.8%). Diarrhea was rare, with only 2.5% of patients reporting this symptom. Compared with the non-severe group, the frequencies of fever, dry cough, sputum production, fatigue, and shortness of breath were much higher in the severe group (Table 1).

Patients were also divided into imported and local disease groups by epidemiological history. There were no significant differences in the parameters described above between the

two groups; however, family cluster infections were more common in the local group (Table S1).

Laboratory and radiographic findings

At admission leukopenia was found in 16.7% of patients, neutropenia in 18.2%, and lymphopenia in 33.5% (Table 2). Other routine blood indices were within the normal ranges. However, the percentages of patients with increased leukocytes and neutrophils, and lower levels of lymphocytes were greater in the severe group than in the non-severe group. In addition, LDH, CK, and aspartate aminotransferase (AST) levels on admission were higher in the severe group than in the non-severe group: LDH: 260 U/L (IQR: 187-418) vs. 179U/L (IQR 148-218); CK: 114 U/L (IQR 68-219.5) vs. 69 U/L (IQR 49-104); AST: 32.4 U/L (IQR 21.7-49) vs. 19.4 U/L (IQR 16.2–27.1). Albumin (ALB) level was decreased in 51.3% of all patients, and more patients in the severe group had decreased ALB levels than in the non-severe group (93.1% vs. 45.2%, $P < 0.001$).

Among all patients, univariate analysis indicated that age, sex, imported disease, incubation period, interval between hospital admission and symptom onset, any coexisting medical condition, leukocyte count, neutrophils count, lymphocyte count, PCT, LDH, CK, ALB, AST, and D-dimer were associated disease severity. Thus, these variables were included in the multivariate logistic regression. The multivariate analysis indicated that age 50-64 years (reference 15-49 years), male sex, and decreased ALB level were independently associated with disease severity.

On admission, 38 (14%) patients in the non-severe group had no abnormalities on chest CT scan, while all patients in the severe group had pneumonia. Bilateral pneumonia (67.6%)

and multiple small patchy shadows and ground-glass shadows (62.1%) were the most common findings (Table 2). Pneumonia was defined as appearance of symptoms of fever, coughing, or dyspnea, and chest CT showing multiple small patchy shadows and interstitial changes in one or both lungs at early stage, then progresses to multiple ground-glass shadows, and infiltration shadows later on both lungs. Compared to the non-severe group, the severe group was more likely to have bilateral involvement (95.6% vs. 61.3%, $P < 0.001$) and a pleural effusion (15.6% vs. 3.9%, $P = 0.007$). Chest CT scan pattern were similar between the imported and local disease groups (Table S2).

Upper respiratory throat swab samples were collected from all patients at admission, and 151 specimens were positive for the ORF1ab gene, with a median Ct value of 34. Of these patients, 28.8% had higher viral loads (Ct values < 30), while 74.2% had low viral loads (Ct values 30 to 40). A total of 158 specimens were positive for the N gene, with a median Ct value of 32, and 41.8% of the specimens had higher viral loads. The levels of viral RNA were no difference between the severe and the non-severe group. There was no significant difference in viral load between imported and local disease cases (Table S2).

Complications and treatment

During hospitalization, the most common complication was pneumonia (86%), followed by ARDS (7.6%) and disseminated intravascular coagulation (DIC) (1.5%). The rates of all complications were higher in patients with severe disease than in those with non-severe disease. A total of 237 patients (86.2%) received empiric antibiotic treatment, 226 (82.2%) received antiviral therapy, 64 (23.3%) received systemic corticosteroid treatment, and 26 (9.5%) received immunoglobulin therapy. Additionally, 6 patients (2.2%) were administered antifungal medications.

Approximately half of the patients (55.6%) received oxygen, and 10.2% of patients required non-invasive ventilation. Eleven patients (4.0%) required invasive mechanical ventilation, and 6 of the 11 patients received extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) as salvage therapy. As expected, these treatments were used in significantly more patients with severe disease as compared to those with non-severe disease (non-invasive ventilation: 55.6% vs. 1.3%, $P < 0.001$; invasive mechanical ventilation: 24.4% vs. 0%, $P < 0.001$; ECMO: 13.3% vs. 0%, $P < 0.001$; CRRT: 13.3% vs. 0%, $P < 0.001$) because application of these treatments were included in the WHO's definition of severe disease. As of February 10, 2020, 229 patients (83.3%) were still hospitalized. A total of 38 patients (13.8%) had been discharged and 8 patients (2.9) had been transferred to another hospital due to serious illness. As of February 10, no patient had died.

Discussion

We investigated the epidemiological, clinical, and laboratory characteristics of 275 patients with COVID-19 in Guangzhou, Guangdong, which the greatest affected province outside of Hubei. This is the largest sample size outside Wuhan, the center of this epidemic as we know so far. The most common symptoms were fever and dry cough, and approximately 16% of the patients had severe disease. There were no healthcare workers in the patient sample, no cases of in-hospital infection, and no deaths at the time this report was prepared.

Many studies(10, 11) regarding SARS-CoV-2 have been published recently. In contrast to studies from city of Wuhan and Zhejiang province, in which most of the patients were males, slightly more than half of our patients were females (53.3%). Furthermore, patients in

the present study had milder disease with respect to a lower frequency of symptoms such as fever, dry cough, and shortness of breath. The rates of severe cases and mortality in Guangzhou were much lower than reported in Wuhan (16.3% and 0%, respectively), which is similar to the rates reported in Zhejiang(11). The rate of gastrointestinal symptoms was low in our study, which is consistent with early reports from Wuhan but is contradict to recent USA report a gastrointestinal symptoms rate of 61% (12). This discrepancy may be attributed to the difference in clinical characteristics between populations or change in the virus. However, further studies should be conducted to investigate this issue. The number of infected patients increased sharply in a short period and medical resources were in short supply, which delayed diagnosis and treatment for many patients. In addition, early diagnosis, isolation, and treatment in Guangzhou might have collectively contributed to the marked reduction in the mortality rate.

In order to further evaluate the relation between source of infection and disease severity, patients were divided into an imported group and a local group based on epidemiological history. Clinical characteristics and laboratory test results were similar between the groups, but the proportion of imported cases was higher in the severe group (80%). However, this association was not significant in the multiple logistic regression.

SARS-CoV viral particles damage the cytoplasmic component of lymphocytes, and results in lymphocyte apoptosis. Thus, patients infected with SARS-CoV are likely to exhibit lymphopenia. A prior study reported that 35% of patients with non-severe SARS-CoV infections had mild lymphopenia(13). Lymphopenia is a prominent feature of severe Middle East respiratory syndrome (MERS) infections(14), and it is common in patients with severe SARS-CoV infections(13). In our study, 60% of patients with severe infections had some

degree of lymphopenia. This suggests that lymphopenia in SARS-CoV-2 infections may be related to the severity of the disease.

Patients who are older, and those with multiple underlying diseases are more likely to develop severe disease(15). Another study demonstrated that patients treated in the ICU were more likely to be older and to have underlying comorbidities, dyspnea, and anorexia than patients who did not require ICU admission(10). This is consistent with the results of our study. Studies of other viral diseases, such as rabies, have indicated that the incubation period of viral diseases is significantly related to the severity of the disease. Shorter incubation periods are associated with more serious disease, and this is related to the number of cells initially infected by the virus. However, no studies have examined the relation between the incubation period of COVID-19 and disease severity so far. We found that the incubation period was shorter in patients with severe disease, which suggests that the incubation period of COVID-19 may be related to disease severity. In addition, patients with bilateral pneumonia diagnosed on admission by CT were more likely to develop severe disease(16). So its important to process chest CT scan soon after admission.

Multivariate logistic regression analysis indicated that older age, male sex, and lower albumin level were independently associated with severe SARS-CoV-2 infection. ALB is synthesized by hepatocytes, and is the most abundant protein in plasma. Gatta et al.(17) reported that hypoalbuminemia was one of the most important factors affecting the prognosis of patients with sepsis. Peires et al. (18)showed that a decrease of ALB level in patients with sepsis indicated worsening of the disease and a poor prognosis. The mechanism of ALB reduction due to sepsis is considered to be due to the excessive inflammatory reaction of the body. The inflammatory reaction leads to the release of oxygen free radicals and prostaglandins from Kupffer cells, which can inhibit the synthesis of

ALB by the liver, and promote the consumption and decomposition of protein, thus leading to hypoalbuminemia. So its important to evaluate the ALB levels dynamically in these patients.

RT-PCR analysis of respiratory or fecal samples, together with serological testing, can confirm the diagnosis of SARS-CoV infection in most SARS patients. However, the sensitivity of detecting viral RNA is reported to be 16.4% in nasal swabs, 37.3% in throat swabs, and 66.4% in sputum samples(19) . However, testing multiple nasopharyngeal and fecal samples increases the sensitivity of detecting viral RNA(20), and no significant correlation between viral load and severity of SARS-CoV-2 infection has been noted. Considering that the Ct values were comparable between the severe group and the non-severe group, the progression of SARS-CoV-2 respiratory failure might not be due to uncontrolled viral replication, but might be related to immunopathological damage.

This study has several limitations. First, the definition of incubation period should be the time from when the pathogen invades the body to the earliest onset of clinical symptoms. The uncertainty of the exact dates (recall bias) might have inevitably affected the assessment of incubation period. In addition, by the deadline for data collection of this study (February 10, 2020), 229 patients (83.3%) were still hospitalized. At the time of manuscript submission, the onset time in some patients may be shorter than the observation period of 28 days, during which these patients may develop into severe disease and result in deviation of clinical observation characteristics. At present, there is no further follow-up data for these patients due to the urgent need for information that may guide clinical decision-making. Future study with longer follow-up periods should be conducted to validate the findings of this study. The exposure history was recorded based on patient's

self-report at admission when all the patients were sober and able to answer questions. Therefore, there may be inevitably certain degree of subjectivity in the exposure history of the patients. We also found that less than 10% of patients did not know where they were infected, so there may be other unknown potential exposure. Moreover, viral load from other specimen is a potentially useful marker of disease severity; however, only throat swab were available in the present study.

Conclusion

Patients in Guangzhou had relatively milder disease than those in Wuhan, and this may be due to earlier diagnosis and treatment. Older age, male sex, and low ALB level are associated with severe disease.

Notes

Financial support. This work is supported by the Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) and China Medical Board open competition funding (Grant No. 17-271).

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Accepted Manuscript

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020;382:727-733.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* 2020;395:565-574.
3. Zhixin Liu, Xian Xiao, WE XL. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-COV-2.pdf. 2020.
4. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci* 2020.
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507-513.
6. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514-523.
7. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* 2020.
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
9. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCov) infection is suspected. 2020. Available at : <https://www.who.int/health-topics/coronavirus>. Accessed 28 January 2020.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
11. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, Li S-B, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *Bmj* 2020:m606.
12. Nobel YR, Phipps M, Zucker J, Lebowitz B, Wang TC, Sobieszczyk ME, Freedberg DE. Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States. *Gastroenterology* 2020.
13. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, et al. Multiple organ infection and the pathogenesis of SARS. *The Journal of Experimental Medicine* 2005;202:415-424.
14. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. *Antiviral Research* 2017;137:82-92.
15. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine* 2020.
16. Xu X, Yu C, Zhang L, Luo L, Liu J. Imaging features of 2019 novel coronavirus pneumonia. *European Journal of Nuclear Medicine and Molecular Imaging* 2020.
17. Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. *Intern Emerg Med* 2012;7 Suppl 3:S193-199.
18. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, Nicholls J, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *The Lancet* 2003;361:1319-1325.
19. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clin Infect Dis* 2020.
20. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* 2020.

Table 1. Demographic and clinical characteristics of patients with COVID-19

Variable	All Patients (n=275)	Non-Severe Patients (n=230)	Severe Patients (n=45)	P Value
Age, y	49 (34-62)	45 (32-61)	61 (54-71)	<0.001
Age group, %				
<14	5 (1.8)	5 (2.2)	0 (0)	
15-49	136 (49.5)	130 (56.5)	6 (13.3)	
50-64	87 (31.6)	63 (27.4)	24 (53.3)	<0.001
≥65	47 (17.1)	32 (13.9)	15 (33.3)	
Female, %	147 (53.5)	128 (55.7)	19 (42.2)	0.093
Smoking history, %	6 (2.2)	6 (2.6)	0 (0)	0.594
Imported, %	175 (63.6)	139 (60.4)	36 (80.0)	0.013
Coexisting conditions, %				

Any	91 (33.1)	66 (28.7)	25 (55.6)	<0.001
Diabetes	17 (6.2)	12 (5.2)	5 (11.1)	0.245
Hypertension	54 (19.6)	36 (15.7)	18 (40.0)	<0.001
Coronary heart disease	5 (1.8)	4 (1.7)	1 (2.2)	0.594
Cerebrovascular diseases	6 (2.2)	4 (1.7)	2 (4.4)	0.255
Hepatitis B infection*	6 (2.2)	4 (1.7)	2 (4.4)	0.255
Cancers [†]	2 (0.7)	1 (0.4)	1 (2.2)	0.301
Chronic renal disease	4 (1.5)	1 (0.4)	3 (6.7)	0.015
Familial cluster,%	112 (40.7)	98 (42.6)	14 (31.1)	0.145
Fever, %	194 (70.5)	154 (67.0)	40 (88.9)	<0.001
Highest temperature before hospital admission, %				
<37.3	82 (29.8)	77 (33.5)	5 (11.1)	<0.001
37.3-38.0	100 (36.4)	87 (37.8)	13 (28.9)	
38.1-39.0	66 (24.0)	52 (22.6)	14 (31.1)	
>39.0	27 (9.8)	14 (6.1)	13 (28.9)	
Headache, %	15 (5.5)	11 (4.8)	4 (8.9)	0.453
Dry cough, %	154 (56)	119 (51.7)	35 (77.8)	0.001
Sore throat, %	38 (13.8)	31 (13.5)	7 (15.6)	0.712
Sputum production, %	62 (22.5)	43 (18.7)	19 (42.2)	0.001

Fatigue, %	20 (7.3)	10 (4.3)	10 (22.2)	<0.001
Shortness of breath, %	25 (9.1)	12 (5.2)	13 (28.9)	<0.001
Nausea or vomiting, %	8 (2.9)	7 (3.0)	1 (2.2)	1.000
Diarrhea, %	7 (2.5)	5 (2.2)	2 (4.4)	0.714
Incubation period, days	6 (3-9)	6 (3-10)	4 (3-6)	0.004
Interval between admission to hospital and symptom onset, days	4 (2-7)	4 (2-7)	5 (2-9.5)	0.034

Data are presented as medians (interquartile ranges, IQR) and no. (%).

* Hepatitis B infection denoted hepatitis B surface antigen tested positive, with or without elevated alanine or aspartate aminotransferase levels.

† Cancers referred to any malignancy. All cases were stable disease.

P values denoted the comparison between the non-severe group and the severe group.

Table 2. Laboratory and radiographic characteristics of patients with COVID-19

Variable	Normal Range	All Patients (n=275)	Non-Severe Patients (n=230)	Severe Patients (n=45)	<i>P</i> Value
Laboratory					
Leukocyte count, 10 ⁹ /L	3.5–9.5	4.8 (3.8-5.9)	4.7 (3.8-5.9)	5.0 (4.2-6.7)	0.126
Increased, %		10/275 (3.6)	4/230 (1.7)	6/45 (13.3)	0.001
Decreased, %		46/275 (16.7)	41/230 (17.8)	5/45 (11.1)	
Neutrophils count, 10 ⁹ /L	1.8–6.3	2.8 (2.1-3.7)	2.7 (2-3.5)	3.7 (2.7-5.2)	<0.001
Increased, %		13/275 (4.7)	5/230 (2.2)	8/45 (17.8)	<0.001
Decreased, %		50/275 (18.2)	46/230 (20.0)	4/45 (8.9)	
Lymphocyte count, 10 ⁹ /L	1.1–3.2	1.4 (1-1.9)	1.5 (1.1-2)	1 (0.7-1.3)	<0.001

Increased, %		6/275 (2.2)	6/230 (2.6)	0 (0)	<0.001
Decreased, %		92/275 (33.5)	65/230 (28.3)	27 (60.0)	
Monocyte count, 10 ⁹ /L	0.1–0.6	0.4 (0.3-0.5)	0.4 (0.3-0.5)	0.3 (0.2-0.4)	0.160
Platelet count, 10 ⁹ /L	125–350	183 (145-228)	187 (149-232)	160 (127-195)	0.001
Haemoglobin level, g/L	130–175	136 (125-146)	137 (127-148)	132(120-142)	0.013
Total bilirubin, µmol/L	0–21	9.1 (6.4-13)	8.9 (6.4-12.3)	10 (6.6-15.9)	0.129
Albumin, g/L	45–55	40 (37-43)	41 (38-44)	34 (32-37)	<0.001
Increased, %		1/228 (0.4)	1/199 (0.5)	0/29 (0)	<0.001
Decreased, %		117/228 (51.3)	90/199 (45.2)	27/29 (93.1)	
Aspartate aminotransferase, U/L	15–40	21 (17-29)	19 (16-27)	32 (22-49)	<0.001
Increased, %		44/273 (16.1)	27/229 (11.8)	17/44 (38.6)	<0.001
Decreased, %		45/273 (16.5)	41/229 (17.9)	4/44 (9.1)	
Alanine aminotransferase, U/L	9–50	21 (14-31)	10 (14-28)	23 (14-41)	0.249
Creatinine kinase, µmol/L	50–310	74 (51-114)	69 (49-104)	114 (68-220)	<0.001
Increased, %		10/252 (4.0)	4/211 (1.9)	6/41 (14.6)	0.001
Decreased, %		62/252 (24.6)	57/211 (27.0)	5/41 (12.2)	
Lactose dehydrogenase, U/L	120–250	188 (151-238)	179 (148-218)	260 (187-418)	<0.001
Increased, %		55/252 (21.8)	33/211 (15.6)	22/41 (53.7)	<0.001
Decreased, %		13/252 (5.2)	13/211 (6.2)	0/41 (0)	

Creatinine, μmol/L	57–111	60 (48-77)	59 (48-77)	65 (52-82)	0.261
Increased, %		6/267 (2.2)	2/224 (0.9)	4/43 (9.3)	0.006
Decreased, %		115/267 (43.1)	101/224 (45.1)	14/43 (32.6)	
C-reactive protein level, mg/L	<10	<10 (<10-27)	<10 (<10-19)	33 (15-63)	<0.001
Procalcitonin level, ng/mL	<0.5	0.04 (0.03-0.08)	0.04 (0.03-0.06)	0.1 (0.05-0.2)	<0.001
Prothrombin time, s	11–15	13.5 (13-14)	13.5 (13.1-14)	13.2 (12.7-14)	0.280
D-dimer, μg/L	<1000	1030 (640-1480)	990 (620-1415)	1560 (850-1870)	0.003
Increased,%		132/255 (51.8)	107/220 (48.6)	25/35 (71.4)	0.012
Sodium, mmol/L	137-147	140 (138-141)	140 (138-142)	138 (136-139)	<0.001
Potassium, mmol/L	3.5-5.3	3.6 (3.3-3.9)	3.6 (3.4-3.9)	3.4 (3.2-3.8)	<0.001
2019-nCov level of ORF1a/b gene	<40	34 (30-37)	34 (31-37)	35 (28-38)	0.630
<30		39/151 (25.8)	28/121 (23.1)	11/30 (36.7)	0.130
30-40		112/151 (74.2)	93/121 (76.9)	19/30 (63.3)	
2019-nCov level of N gene	<40	32 (28-36)	33 (27-36)	32 (29-36)	0.589
<30		66/158 (41.8)	53/126 (42.1)	13/32 (40.6)	0.883
30-40		92/158 (58.2)	73/126 (57.9)	19/32 (59.4)	
Radiologic					
normal, %		38/272 (14.0)	38/227 (16.7)	0/45 (0)	0.003
Bilateral pneumonia, %		184/272 (67.6)	141/227 (62.1)	43/45 (95.6)	<0.001

Unilatera pneumonia, %	50/272 (18.4)	48/227 (21.1)	2/45 (4.4)	0.009
Multiple small patchy shadows and ground-glass shadows, %	169/272 (62.1)	134/227 (59.0)	35/45 (77.8)	0.014
pleural effusion, %	16/272 (5.9)	9/227 (4.0)	7/45 (15.6)	0.007
pleural thickening, %	13/272 (4.8)	7/227 (3.1)	6/45 (13.3)	0.010

Data are presented as medians (interquartile ranges, IQR) and no. (%).

P values denoted the comparison between the non-severe group and the severe group.

Table 3. Complications, treatment and outcomes of patients with COVID-19

Variable	All Patients (n=275)	Non-Severe Patients (n=230)	Severe Patients (n=45)	P Value
Complications, %				
Septic shock	1 (0.4)	0 (0)	1 (2.2)	0.164
Acute respiratory distress syndrome	21 (7.6)	0 (0)	21 (46.7)	<0.001
Disseminated intravascular coagulation	4 (1.5)	0 (0)	4 (8.9)	0.001
Administration of antibiotics medications, %	237 (86.2)	192 (83.5)	45 (100)	0.002
Administration of antiviral medications, %	226 (82.2)	185 (80.4)	41 (91.1)	0.087
Administration of antifungal medications, %	6 (2.2)	0 (0)	6 (13.3)	<0.001
Administration of systemic corticosteroids, %	64 (23.3)	29 (12.6)	35 (77.8)	<0.001
Administration of immunoglobulin therapy, %	26 (9.5)	3 (1.3)	23 (51.1)	<0.001
Oxygen therapy, %	153 (55.6)	108 (47.0)	45 (100)	<0.001
Mechanical ventilation, %				
Invasive	11 (4.0)	0 (0)	11 (24.4)	<0.001
Non-invasive	28 (10.2)	3 (1.3)	25 (55.6)	<0.001
Use of extracorporeal membrane oxygenation, %	6 (2.2)	0 (0)	6 (13.3)	<0.001

Use of continuous renal replacement therapy, %	6 (2.2)	0 (0)	6 (13.3)	<0.001
Intensive care unit admission, %	29 (10.5)	1 (0.4)	28 (62.2)	<0.001
Clinical outcomes, %				
Discharge	38 (13.8)	36 (15.7)	2 (4.4)	
Death	0 (0)	0 (0)	0 (0)	
Staying in hospital	229 (83.3)	194 (84.3)	35 (77.8)	<0.001
Transfer to another hospital	8 (2.9)	0 (0)	8 (17.8)	

Data are presented as no. (%).

P values denoted the comparison between the non-severe group and the severe group.

Table 4. Association between different parameters and severe cases by multivariate logistic regression

Parameter	OR	95% CI	P value
Age			
<14	0.000	0.000	
50-64	23.519	2.603-212.525	0.005
≥65	8.878	0.923-85.414	0.059
Male	4.173	1.151-15.135	0.030
Albumin	15.998	1.833-139.591	0.012

OR denoted odds ratio, CI denoted confidence interval